DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award | HT942524KCRPAKCIECSA

Opportunity Information: Apply for HT942524KCRPAKCIECSA

The DoD Kidney Cancer Research Program (KCRP) Academy of Kidney Cancer Investigators (AKCI) Early-Career Scholar Award is a four-year grant mechanism built around a structured, virtual mentoring academy rather than a traditional standalone career development award. The core idea is to accelerate the development of junior faculty into independent, highly productive kidney cancer researchers by pairing each Early-Career Scholar (ECS) with a Designated Mentor and then plugging that pair into a larger, interactive national network. The academy format is meant to create sustained momentum through regular scientific exchange, career guidance, collaboration, and exposure to advocacy perspectives, with an overall goal of strengthening the kidney cancer research workforce and speeding progress in the field.

A central feature of this opportunity is the expectation that the ECS will do more than just run a funded project. Scholars are expected to actively participate in the AKCI community through monthly webinars, annual workshops, and ongoing communication and collaboration with other academy members, including fellow scholars, mentors, and the Academy Leadership Team. Engagement with the kidney cancer advocacy community is also part of the model, reflecting an emphasis on keeping research connected to patient and community needs. The Academy Leadership Team, led by an Academy Director and Deputy Director, serves as a coordinating and support structure across the academy, helping track scholar progress, facilitating connections, and supporting both scientific and professional development. Beyond research skills, the program explicitly aims to build leadership and practical competencies needed to win funding and manage a laboratory or research team.

The award supports a kidney cancer research project led by the ECS, who is named as the Principal Investigator on the application. Projects can be basic, translational, and/or clinical in nature, but they must not be clinical trials under the federal definition (45 CFR 46.102). In other words, studies can involve human subjects, human specimens, or human data, and can include observational clinical research such as biomarker studies, diagnostic or detection research (including imaging), mechanism-of-disease work in humans, epidemiology, health disparities, outcomes research, or health services research, as long as participants are not prospectively assigned to an intervention to evaluate health outcomes. Applicants must include preliminary data to demonstrate feasibility, although that supporting data does not have to come directly from kidney cancer research as long as it credibly supports the proposed approach.

The mentoring structure is intentionally flexible and designed to broaden access to expertise. The Designated Mentor does not have to be at the same institution as the ECS, which is meant to help early-career investigators who may lack strong kidney cancer mentorship locally. The KCRP specifically encourages applications from early-career scholars who face resource constraints that limit their ability to commit to kidney cancer research, such as limited access to specialized tools, limited collaboration opportunities, or the absence of a qualified mentor at their home institution; those barriers should be clearly described in the application. The ECS and mentor are responsible for crafting the scholar's career development plan and for designing and executing the proposed research, while the academy provides the broader environment, networking, and accountability structure. The ECS must clearly communicate a serious commitment to a long-term career focused on kidney cancer research and to contributing to the growth and culture of the AKCI.

Mentor expectations are substantial and are designed to expand mentorship capacity across the academy, not just within a single scholar-mentor relationship. The Designated Mentor must have a strong record of training and mentoring early-career investigators and must also agree to serve as a Secondary Mentor to another ECS within the AKCI. Mentors are limited to one primary mentorship (the applicant pair) and one secondary mentorship. The announcement also notes that applicants may not list the Dean of the Academy as the Designated Mentor. Both the ECS and Designated Mentor must attend Department of Defense KCRP AKCI workshops, including a multi-day workshop every two years and a one-day workshop in alternate years, reinforcing the program's emphasis on active participation and cohort-building.

While the science can be broad within kidney cancer, the announcement highlights several cross-cutting emphasis areas that applicants are encouraged to consider when appropriate and aligned with KCRP priorities. These include nuclear medicine approaches that could improve early diagnosis and targeted treatment through advanced imaging or precision theranostics; women's health considerations, including analysis of sex as a biological variable and relevance to outcomes for women; and alignment with recommendations from the congressionally mandated Metastatic Cancer Task Force, particularly research aimed at accelerating progress for advanced or recurrent disease. The program also stresses rigorous study design and transparent reporting practices to improve reproducibility and translational value, pointing applicants toward established best practices such as randomization, blinding, sample-size justification, and clear data handling plans. In addition, the DoD strongly encourages military service involvement and multidisciplinary partnerships across academia, industry, the military services, the Department of Veterans Affairs, and other federal agencies, especially when those collaborations provide unique populations, infrastructure, or data resources; proposals relying on unique resources must explain access at submission and how access will be maintained throughout the project.

From an administrative and funding standpoint, awards are issued as grants. The anticipated maximum for direct costs over the full period of performance is $725,000 for the four-year project. The agency expects to commit roughly $2.32 million total to fund about two awards, though actual funding depends on federal fund availability and the results of peer and programmatic review. The opportunity is run by the Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), under CFDA 12.420, and eligibility is listed as unrestricted. The original application closing date is October 15, 2024. Awards supported with FY24 funds are expected to be made no later than September 30, 2025, and FY24 funds associated with awards are anticipated to be available for use until they expire on September 30, 2030, reflecting the federal period-of-availability rules for the underlying appropriation.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Academy of Kidney Cancer Investigators - Early-Career Scholar Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-07-11.
• Applicants must submit their applications by 2024-10-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524KCRPAKCIECSA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: